Claims
- 1. A method for treatment of neuropsychiatric disorders which comprises administration of a D-serine transport inhibitor at a dose sufficient to enhance NMDA receptor-mediated neurotransmission in vivo.
- 2. The method of claim 1 wherein the disorder is associated with decreased N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission.
- 3. The method of claim 1 wherein the disorder is a psychotic disorder.
- 4. The method of claim 3 wherein the psychotic disorder is schizophrenia
- 5. The method of claim 1 wherein the disorder is Alzheimer's disease, bipolar illness, depression and anxiety disorders, stroke or epilepsy.
- 6. The method of claim 1 wherein the disorder is age associated memory impairment, closed head injury or attention deficit disorder.
- 7. The method of claim 1 wherein such agent is administered orally.
- 8. The method of claim 1 wherein a D-serine transport inhibitor is administered parenterally.
- 9. A method for augmentation of N-methyl-D-aspartate receptor-mediated neurotransmission in vivo which comprises administration of a D-serine transport antagonist.
- 10. The method of claim 1 or 9 wherein the antagonist is an inhibitor of D-serine transport mediated through system ASC.
- 11. The method of claim 1 or 9 wherein the antagonist is an inhibitor of systems L, N, A or Gly.
- 12. The method of claim 1 or 9 wherein the antagonist is an inhibitor of alanine-sensitive D-serine transport.
- 13. The method of claim 1 or 9 where the antagonist is an inhibitor of alanine-insensitive D-serine transport.
- 14. The method of claim 1 or 9 wherein the agent is glycyldodecylamide, D-serine dodecylamide or D-alanine dodecylamide.
- 15. The method of claim 1 or 9 wherein the agent is used in combination with typical or atypical antipsychotics administered orally, parenterally or by depot formulation.
- 16. The method of claim 1 or 9 wherein the agent is used in combination with other treatments commonly used in schizophrenia, including but not limited to antidepressants, mood stabilizers, or antianxiety agents.
- 17. The method of claim 1 or 9 wherein the agent is used in combination with a glycine transport inhibitor.
- 18. A composition for treating schizophrenia incorporating a D-serine transport inhibitor.
- 19. A composition of claim 18, wherein the inhibitor is glycyldodecylamide, D-serine dodecylamide or D-alanine dodecylamide.
- 20. A composition of claim 18 wherein the inhibitor is a derivative of serine or alanine having effectiveness in inhibiting D-serine transport in vivo.
- 21. A composition of claim 18 wherein the D-serine transport inhibitor is combined with a typical or atypical antipsychotic agent administerable orally or parenterally.
- 22. A composition of claim 20 wherein the derivative is a hydrophobic derivative of serine or alanine.
- 23. A composition of claim 22 wherein the derivative is serine or alanine having a hydrophobic group linked to at least one of the C- and N-terminus.
- 24. A composition where the hydrophobic group is selected from the group consisting of alkyl (C1-C13), unsubstituted or substituted phenyl, phenylalkyl (C1-C13), cyano, halogen and or haloalkyl (C1-C13)..
- 25. A method of claim 1 wherein a composition of claim 20 is used.
- 26. A method of claim 9 wherein a composition of claim 20 is used.
RELATED APPLICATION
[0001] The present application is a continuation-in-part of U.S. application Ser. No. 09/365,889 filed Aug. 3, 1999.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09365889 |
Aug 1999 |
US |
Child |
10066657 |
Feb 2002 |
US |